asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

Rikant Pittie’s visionary investment emerges as the pinnacle to become the highest Investment in ‘Indian Angels’ Show season 1

by asianprimenews0603

Mumbai, December 18, 2023: Mr. Rikant Pittie, the visionary Co-Founder of EaseMyTrip.com, has reaffirmed his commitment to fostering innovation and supporting promising startups with a substantial investment across multiple episodes of the ‘Indian Angels’ show streaming on Jio Cinema.

Since the onset of the groundbreaking show, Mr. Pittie has emerged as a stalwart investor, strategically deploying funds in ventures spanning diverse industries. His strategic investments exemplify a dedicated commitment to nurturing startups with the tenacity to overcome challenges and achieve success.

In a compelling series of strategic investments featured on Jio Cinema’s ‘Indian Angels,’ Mr. Rikant Pittie has demonstrated a versatile and unwavering commitment to supporting startups. The initial episodes (1 and 2) witnessed his endorsement of Atpata by Taste and Happie Curves, showcasing his dedication to the FMCG and women’s clothing markets. Episodes 3 and 4 marked investments in ReGrip, Shakti Wearables, and Vastu Ghee, revealing Mr. Pittie’s keen insight into diverse industries, spanning from automobiles (tyres) to Food and Beverage (Dairy) and Smart Wearables (Women’s safety). Episode 5 stood out as a significant milestone when Mr. Pittie continued his impressive streak, making a high-impact investment in Sohamm Snacks. Concluding the series on a positive note, Episode 8 highlighted Mr. Pittie’s commitment to modernizing oral health routines with a strategic investment in Team Habbits. This investment journey reflects Mr. Pittie’s diverse interests and steadfast support for innovative ventures across various sectors.

“Venturing into diverse industries with strategic investments is more than a financial commitment for me; it’s a belief in the power of innovation. These startups represent the future, and my support signifies a commitment to nurturing transformative ideas that have the potential to redefine their respective sectors. In every investment, I see a unique opportunity to contribute to the evolving landscape of entrepreneurship, supporting ventures that break away from the ordinary and pave the way for a more dynamic and innovative future.” Rikant Pittie, Co-Founder, EaseMyTrip.

Mr. Rikant Pittie entered the entrepreneurial arena at the tender age of 16, demonstrating early leadership and business acuity. His instrumental role in the development of EaseMyTrip, along with the establishment of its technological framework, showcases a profound comprehension of the intricacies inherent in building businesses from the ground up. Participating alongside five distinguished panellists on the ‘Indian Angels’ show, Mr. Pittie’s strategic investments in seven ventures in the show underscore his dedicated commitment to nurturing startups with the tenacity to overcome challenges and achieve success.

Claiming to be the world’s first angel investment show on OTT, ‘Indian Angels’ is produced by Digikore Studios and was released on November 03, 2023. It is a groundbreaking show, transforming the startup industry and entrepreneurial ecosystem with its innovative format. In addition to the angel investors supporting ventures, the first-of-its-kind show enables viewers to become investors themselves.

Share

Related posts

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

Towards a Future of One-of-a-Kind Cherished Vehicles Aligned with Personal Values

asianprimenews

God’s Own Country Welcomes Lyca Productions

asianprimenews